2099-68-5

Usage

Uses

Used in Pharmaceutical Industry:
4,5α-Dihydro Norethandrolone is used as an active pharmaceutical ingredient for its anabolic and androgenic effects. It is particularly beneficial for conditions that require muscle growth, strength enhancement, and hormone regulation.
Used in Sports Performance Enhancement:
As a performance-enhancing drug, 4,5α-Dihydro Norethandrolone is used by athletes to improve their physical performance, increase muscle mass, and enhance overall strength. However, its use is regulated and monitored due to its status as a controlled substance.
Used in Research and Development:
In the field of scientific research, 4,5α-Dihydro Norethandrolone serves as a crucial compound for studying the effects of anabolic steroids on the human body. This helps in understanding the potential therapeutic applications and side effects associated with its use.
Used in Drug Testing and Doping Control:
4,5α-Dihydro Norethandrolone is utilized in drug testing protocols to detect the use of banned substances in sports. Its presence in an athlete's system can indicate the use of performance-enhancing drugs, leading to potential sanctions and penalties.

Upstream product

• 52-78-8 norethandrolone 
• 68-22-4 norethisterone 
• 6795-60-4 17-hydroxy-19-nor-17α-pregna-4,20-dien-3-one 
• 7253-95-4 19-nor-5α,17α-pregnane-3β,17β-diol 
• 6424-06-2 17-hydroxy-19-nor-5α,17βH-pregn-20-en-3-one 
• 52-79-9 [3H]-5alpha-Dihydrorethindrone 

Downstream Products

• 6961-15-5 19-nor-5α,17α-pregnane-3α,17β-diol 
• 7253-95-4 19-nor-5α,17α-pregnane-3β,17β-diol 

Relevant academic research and scientific papers

Equine metabolites of norethandrolone: Synthesis of a series of 19-nor-17α-pregnanediols and 19-nor-17α-pregnanetriols

A range of 19-nor-17α-pregnanediols and 19-nor-17α-pregnanetriols have been synthesized and used to confirm the structures of major equine urinary metabolites of the synthetic anabolic steroid norethandrolone (1). 19-Nor-5α,17α-pregnane-3α,17β-diol (2), 19-nor-5α,17α-pregnane-3β,17β-diol (4), 19-nor-5β, 17α-pegnane-3α,17β-diol (6), and 19-nor-5β,17α-pregnane-3β,17β-diol (7) were prepared by stereoselective reduction of the 3-ene-4-one of norethandrolone. The 19-nor-5α,17α-pregnane-3β,16α,17β-triol (8) and 19-nor-5α,17α-pregnane-3β,16β, 17β-triol (9) were prepared from 19-nortestosterone (11) by multistep processes in which the critical step involved Grignard additions to 16-acetoxy-17-ones. The triols (20R)-19-nor-5α,-17α-pregnane-3β,17β,20-triol (22) and (20S)-19-nor-5α, 17α-pregnane-3β,17β,20-triol (23) were prepared from norethindrone (24) by initial selective A-ring reduction, then subsequent modification of the 17-ethynyl group. By comparison of these compounds with post-administration equine urine samples it was possible to establish A-ring reduction with 3β,5α stereochemistry as well as non-stereospecific 16-hydroxylation and 20-hydroxylation as significant metabolic pathways affecting norethandrolone in the horse.